Skip to main content
Caplight Logo









Omniose

Omniose

Private
Saint Louis, MichiganHealthcare & Life Scienceshttps://omniose.com/

Last Round

Grant

Sep 27, 2023

Total Funding Raised

$12.7M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Omniose is a biotechnology company that develops polysaccharide conjugate vaccines against bacterial threats using its proprietary bioconjugation platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

bioconjugationconjugate vaccinesvaccine platformenzymatic glycosylationbacterial vaccinedrug discoverybiotech R&Dglycoengineeringvaccine manufacturinginfectious diseasesynthetic biologymultidrug-resistant bacteriabiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Omniose Comparables

Compare Omniose with similar companies based on industry and business-model similarity.

Omniose comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
LimmaTech Biologics
88%
Glycovax Pharma
81%
Baxiva AG
78%

Omniose Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 27, 2023
GrantOct 11, 2022
GrantAug 20, 2020
GrantFeb 21, 2020
SeedJan 1, 2019
Grant
Nov 3, 2017

Key People

Founding team and executive leadership

Christian Harding

Chief Scientific Officer Co-Founder

Founding Team

Timothy Cooke

Chief Executive Officer

Executive Team

Omniose Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 115% MoM, from 1.4K to 3.1K.

  • Sep 27, 2023

    $3M raised from National Institute of Allergy and Infectious Diseases

Omniose Filings

Explore SEC and related filing metadata, where available.

Omniose filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Omniose's valuation, stock price, and market status.

Is Omniose a public or private company?

Omniose is a private company.

What is the current stock price of Omniose?

Omniose is a private company with no public stock price. No recent secondary market data is available.

How much is Omniose worth (valuation)?

Valuation information for Omniose is not publicly available.

Can I buy Omniose stock?

Omniose shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Omniose's last funding round?

Omniose's most recent funding round was Grant on September 27, 2023.

Who are the main investors in Omniose?

Key investors in Omniose include National Institute of Allergy and Infectious Diseases, Arch Grants, NIH RADx, BioGenerator Ventures.

Will Omniose IPO soon?

No public IPO plans have been announced for Omniose.

How can I track Omniose secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Omniose's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSaint Louis, Michigan
Employee Range21
Year Founded2016
Last FundingSep 27, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?